Skip to main content
V. Gambardella on Muck Rack

V. Gambardella

As seen in: Annals of Oncology, Cancer Treatment Reviews
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with V.

Contact V., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Checkpoint inhibitors for gastroesophageal cancers: Dissecting heterogeneity to better understand their role in first line and adjuvant therapy

|
By V. Gambardella, A. Cervantes, T. Fleitas, E.C. Smyth
| annalsofoncology.org
Highlights: • Adding nivolumab to first line chemotherapy can improve survival in first-line advanced gastro-esophageal adenocarcinoma • The benefit observed is most convincing in tumors with a high expression of PD-L1 (CPS ≥5) • Pembrolizumab gives a similar benefit in esophageal cancer most evident in squamous with high PD-L1 expression (CPS ≥10) • Adjuvant nivolumab increases disease-free survival in esophageal cancers in non-responders to trimodality treatment • Better predictive...
Open in Who Shared Issue with article?

The role of Tumor-Associated Macrophages in Gastric Cancer development and their potential as a therapeutic target

|
By V. Gambardella, J. Castillo, N. Tarazona, F. Gimeno-Valiente
| Cancer Treatment Reviews Verified
Highlights • Tumor immune microenvironment signalling influences tumor progression. • Tumor associated macrophages are characterized by a dual pro- and anti-tumor activity. • Tumor associated macrophages emerge as a potential target for cancer treatment in gastric cancer. Abstract Gastric cancer (GC) represents the fifth cause of cancer-related death worldwide.
Open in Who Shared Issue with article?

Inhibition of PI3K pathway improves anti HER2 treatment efficacy in a panel of HER2 positive gastric cancer cell lines

|
By J. Castillo, V. Gambardella, M. J. Llorca-Cardeñosa, N. Tarazona Llavero
| Annals of Oncology Verified
Inhibition of PI3K pathway improves anti HER2 treatment efficacy in a panel of HER2 positive gastric cancer cell lines V. Gambardella, M.J. Llorca-Cardeñosa, J. Castillo, N. Tarazona Llavero, M. Huerta, S. Roselló Keränen, M. Ibarolla-Villava, G. Ribas, A. Gil and A. Cervantes Dept. Medical Oncology, Biomedical Research institute INCLIVA University of Valencia, Valencia, Spain Background: Gastric cancer (GC) represents a major health problem. HER2, when amplified, is the only validated druggable target.
Open in Who Shared Issue with article?
See all 3 articles